Rebecca Araujo

DocwireNews

Docwire News spoke with Thomas G. Martin, MD, Professor of Medicine and Associate Director of the Myeloma Program at the University of California, San Francisco, about how he approaches treating a patient with high-risk multiple myeloma (MM) experiencing early relapse.This is part three of a four-part series featuring Dr. Martin, Watch <a href="https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/multiple-myeloma-kol-video/defining-high-risk-multiple-myeloma-with-dr-martin/">part one</a>, where he defines high-risk MM, and <a href="https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/multiple-myeloma-kol-video/dr-martin-improving-survival-rates-in-high-risk-multiple-myeloma/">part two</a>, where he highlights some promising research on improving survival in this patient population.Docwire News: How do high-risk cytogenetics impact the treatment strategy for MM when dealing with early relapse?Dr. Martin: I will say two things. The first thing I&rsquo;ll say in terms of early relapse. My decision on early relapse is much dependent on what I&rsquo;ve done in frontline therapy. So If I know somebody who has high-risk disease, they&rsquo;re going to get carfilzomib, lenalidomide, plus dexamethasone (KRd) &hellip; and they&rsquo;re going to get maintenance. And in my mind, the maintenance is going to be a proteasome inhibitor (PI), plus lenalidomide. I do at least a doublet, plus or minus dexamethasone if they can tolerate it. So when they&rsquo;re relapsing, they&rsquo;re already relapsing on a PI, lenalidomide plus or minus dexamethasone. So, that&rsquo;s a tough patient population, I have to think about that.In my mind, I try to put those patients on a clinical trial, if I have one for those people. But if not, then I will actually choose a triplet regimen and it will include a CD38 antibody. The CD38 antibody, because they haven&rsquo;t been exposed to CD38. And in the relapse setting, CD38 has been shown to work very well. &hellip; And then I choose a partner, so the partner could be carfilzomib (K), in my mind. So right now approved is daratumumab, carfilzomib, and dexamethasone. Or we can choose pomalidomide, so approved is daratumumab, pomalidomide, dexamethasone, but also isatuximab, the other CD38 antibody, pomalidomide and dexamethasone. So I&rsquo;ll choose between one of those two. And if they, for whatever reason, had intolerance to the bortezomib and I couldn&rsquo;t keep them on that, and they&rsquo;ve been off bortezomib then I&rsquo;ll definitely go with [daratumumab plus carfilzomib and dexamethasone].If they couldn&rsquo;t tolerate the [lenalidomide] and they were only on bortezomib, then I will definitely I&rsquo;ll go to basically isatuximab, pomalidomide, dexamethasone, or daratumumab, pomalidomide, dexamethasone, one of those. &hellip; Basically the first out of the gate is a CD38 antibody, plus a next generation PI or an immunomodulatory drug (IMiD).And so I think those are really good combinations. So, we&rsquo;re also testing in clinical trials, chimeric antigen receptor (CAR) T cells as part of first to third relapse, and in this setting when they have high-risk disease, I think that actually would be, you give them some induction, you collect their lymphocytes, you give them some bridging therapy, which would be one of those regimens I talked about, and then they get a CAR T. And then we&rsquo;ll have to see whether maintenance after a CAR T is needed in that scenario.But I&rsquo;ll mention one other thing and that is when people relapse, maybe they didn&rsquo;t have high-risk disease when they first presented. When they relapse, I tend to do a bone marrow biopsy with FISH (fluorescence in situ hybridization) testing at relapse, especially first relapse, especially if it&rsquo;s a short first relapse. Because I want to see, is this clone that&rsquo;s driven by one of these high-risk abnormalities?

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Treating Relapsed Patients with High-Risk Multiple Myeloma, with Dr. Martin

Oncology

Docwire News spoke with Thomas G. Martin, MD, Professor of Medicine and Associate Director of the Myeloma Program at the University of California, San Francisco, about how he ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe